179 related articles for article (PubMed ID: 37628609)
1.
Boldrini L; Bardi M
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628609
[TBL] [Abstract][Full Text] [Related]
2. Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database.
Boldrini L; Faviana P; Galli L; Paolieri F; Erba PA; Bardi M
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573332
[TBL] [Abstract][Full Text] [Related]
3. WSB1 regulates c-Myc expression through
Gao X; You J; Gong Y; Yuan M; Zhu H; Fang L; Zhu H; Ying M; He Q; Yang B; Cao J
Acta Pharm Sin B; 2022 Mar; 12(3):1225-1239. PubMed ID: 35530152
[TBL] [Abstract][Full Text] [Related]
4. High expression of WSB1 is associated with poor prognosis in hepatocellular carcinoma and affects epithelial-mesenchymal transition.
Xu H; Han H; Tian G
J BUON; 2020; 25(4):1890-1896. PubMed ID: 33099929
[TBL] [Abstract][Full Text] [Related]
5. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
6. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
7.
Carneiro VL; da Silva HBF; Queiroz GA; Veiga RV; Oliveira PRS; Carneiro NVQ; Pires AO; da Silva RR; Sena F; Belitardo E; Nascimento R; Silva M; Marques CR; Costa RDS; Alcantra-Neves NM; Barreto ML; Cooper PJ; Figueiredo CA
Front Immunol; 2021; 12():622051. PubMed ID: 33692795
[TBL] [Abstract][Full Text] [Related]
8. The WSB1 gene is involved in pancreatic cancer progression.
Archange C; Nowak J; Garcia S; Moutardier V; Calvo EL; Dagorn JC; Iovanna JL
PLoS One; 2008 Jun; 3(6):e2475. PubMed ID: 18575577
[TBL] [Abstract][Full Text] [Related]
9. An
Lu X; Pan X; Wu CJ; Zhao D; Feng S; Zang Y; Lee R; Khadka S; Amin SB; Jin EJ; Shang X; Deng P; Luo Y; Morgenlander WR; Weinrich J; Lu X; Jiang S; Chang Q; Navone NM; Troncoso P; DePinho RA; Wang YA
Cancer Res; 2018 Jul; 78(14):3823-3833. PubMed ID: 29769196
[TBL] [Abstract][Full Text] [Related]
10. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
[TBL] [Abstract][Full Text] [Related]
11. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
12. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
13. The Glypican proteoglycans show intrinsic interactions with Wnt-3a in human prostate cancer cells that are not always associated with cascade activation.
de Moraes GFA; Listik E; Justo GZ; Vicente CM; Toma L
BMC Mol Cell Biol; 2021 May; 22(1):26. PubMed ID: 33947326
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
15. WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.
Kim JJ; Lee SB; Yi SY; Han SA; Kim SH; Lee JM; Tong SY; Yin P; Gao B; Zhang J; Lou Z
Cell Res; 2017 Feb; 27(2):274-293. PubMed ID: 27958289
[TBL] [Abstract][Full Text] [Related]
16. WSB1: from homeostasis to hypoxia.
Haque M; Kendal JK; MacIsaac RM; Demetrick DJ
J Biomed Sci; 2016 Aug; 23(1):61. PubMed ID: 27542736
[TBL] [Abstract][Full Text] [Related]
17. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
18. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
Yang X; Chen MW; Terry S; Vacherot F; Chopin DK; Bemis DL; Kitajewski J; Benson MC; Guo Y; Buttyan R
Cancer Res; 2005 Jun; 65(12):5263-71. PubMed ID: 15958572
[TBL] [Abstract][Full Text] [Related]
19. The polycomb group protein EZH2 is involved in progression of prostate cancer.
Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RG; Otte AP; Rubin MA; Chinnaiyan AM
Nature; 2002 Oct; 419(6907):624-9. PubMed ID: 12374981
[TBL] [Abstract][Full Text] [Related]
20. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
Wang D; Lu G; Shao Y; Xu D
Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
